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Abstract 
 
 
Arsenic trioxide (ATO) has potent clinical activity in the treatment of patients with acute 
promyelocytic leukemia (APL), but is much less efficient in acute myeloid leukemia (AML) 
lacking t(15;17) translocation. Recent studies indicated that the addition of mammalian target 
of rapamycin (mTOR) inhibitors might increase the sensitivity of malignant cells to ATO. 
The aim of this study was to test for the possible synergistic effects of ATO and rapamycin at 
therapeutically achievable doses in non-APL AML cells. In HL-60 and U937 cell lines, the 
inhibitory effects of low concentrations of ATO and rapamycin were synergistic and more 
pronounced in U937 cells. The combination of drugs increased apoptosis in HL-60 cells and 
increased the percentage of cells in G0/G1 phase in both cell lines. In U937 cells, rapamycin 
alone increased the activity of mitogen-activated protein kinase/extracellular signal-regulated 
kinase (MAPK/ERK) and the addition of ATO decreased the level of phosphorylated ERK, 
Ser473 phosphorylated Akt and antiapoptotic Mcl-1 protein. Primary AML cells show high 
sensitivity to growth-inhibitory effects of rapamycin alone or in combination with ATO. The 
results of this study revealed the mechanism of the synergistic effects of two drugs at 
therapeutically achievable doses in non-APL AML cells. 
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Introduction 
 
 Arsenic trioxide (ATO) has potent clinical activity in the treatment of patients with 
acute promyelocytic leukemia (APL), a rare form of acute myeloid leukemia (AML) carrying 
typical t(15;17) translocation [1]. Differentiation therapy of APL with all-trans retinoic acid 
(ATRA) in combination with chemotherapy induces complete remission in more than 90% of 
patients, and the introduction of ATO into treatment of refractory or relapsed APL further 
improves the clinical outcome of the disease. The latest results of clinical studies instituting 
ATO in first-line treatment showed that ATRA plus arsenic trioxide might be superior to 
ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL, 
suggesting the possibility of leukemia treatment without any DNA-damaging chemotherapy 
[2]. Mechanistically, both ATRA and ATO act on the promyelocytic leukemia (PML)/retinoic 
acid receptor α (RARα) fusion protein, which is encoded by the t(15;17) translocation typical 
for APL. Pharmacological doses of ATRA bind to RARα, relieve a transcription block and 
allow granulocytic differentiation, while ATO binds directly to the PML moiety, stimulates 
ubiquitination and degradation of PML-RARα, and induces apoptosis or partial differentiation 
of leukemia cells [3]. Importantly, the combination of ATRA and ATO promotes clearance of 
PML-RARα+ leukemia-initiating cells (LIC), resulting in APL eradication in murine models 
and patients [4]. In other types of AMLs, much higher concentrations of ATO are needed for 
antiproliferative effects, and the mechanisms of ATO-mediated responses are only partially 
understood [5-7]. However, many recent studies suggest a therapeutic potential of ATO in 
non-APL AMLs, especially in combination with drugs that target proliferative or survival 
pathways [8-10].  
 The phosphatydilinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) pathway is one of the principal signaling mechanisms regulating cell growth, 
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survival, proliferation and metabolism [11]. The most established inhibitors of the pathway 
are mTOR inhibitors, rapamycin and its analogs (rapalogs), which have been used as 
immunosuppressants for decades. Although rapalogs have been shown to exert 
antiproliferative and differentiative effects on AML cells in vitro [12, 13], clinical trials have 
revealed only a modest efficacy when they are used as a single agent [11]. However, several 
recent studies indicated that the addition of ATO may increase the sensitivity of malignant 
cells to mTOR inhibitors; ATO-mediated degradation of PML abolished resistance of 
glioblastoma cells to rapamycin [14], ATO synergized with everolimus to induce cytotoxicity 
of ovarian cancer cells [15], and anti-tumor effects of rapamycin in breast cancer were 
enhanced by the addition of ATO [16]. In studies using primary hematopoietic progenitors 
from patients with AML, Altman et al. [17] found that pharmacological inhibition of mTOR 
enhances the suppressive effects of ATO on leukemic progenitor colony formation.  
 Our previous studies suggested that rapamycin-mediated enhancement of the 
expression of differentiation markers in AML cell lines depends on the activity of the 
PI3K/Akt pathway and that the effect is not common to all differentiation inducers [18-20]. 
The aim of the present study was to investigate the possible synergistic effects of ATO and 
rapamycin on the proliferation, survival and differentiation of AML cell lines and primary 
AML cells that lack typical t(15;17) translocation. 
 
 
Materials and methods 
 
Chemicals and reagents 
Arsenic trioxide (A1010) was obtained from Sigma (St. Louis, MO), dissolved in 1M NaOH 
to a concentration of 100 mM and further diluted in RPMI-1640 to a stock concentration of 1 
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mM. Rapamycin (#553210), all-trans retinoic acid (ATRA) (#554720) and PD 98059 
(#513000) were purchased from Calbiochem (San Diego, CA) and dissolved in 100% DMSO 
to stock concentrations of 20 µM, 1mM and 50 mM, respectively. Thiazolyl blue tetrazolium 
bromide (for MTT assay, M2128), color markers, bovine serum albumin (BSA), Triton X-
100, sodium dodecyl sulfate (SDS), leupeptin, phenylmethylsulfonyl fluoride (PMSF), 
propidium iodide (PI), RNase A, Igepal and monoclonal anti-β-actin antibody (#A5441) were 
purchased from Sigma; enhanced chemiluminescence (ECL) substrate for the detection of 
horseradish peroxidase (HRP) was from Pierce (Rockford, IL); and RPMI-1640, fetal bovine 
serum (FBS) and penicillin/streptomycin were from Gibco/Invitrogen (Grand Island, NY). 
Cell lysis buffer (#9803) and antibodies against Mcl-1 (#5453), total S6K (#9202), 
phosphorylated (Thr389) S6K (#9205), total p44/42 mitogen activated protein kinase MAPK 
(#9102), phosphorylated (Thr202/Tyr204) MAPK (#9101), total Akt (#4691), phosphorylated 
(Ser473) Akt (#4060), secondary HRP-conjugated anti-rabbit immunoglobulin G (IgG) 
(#7074) and anti-mouse IgG (#7076) were obtained from Cell Signaling Technology 
(Beverly, MA). The annexin V - fluorescein isothiocyanate (FITC) kit (IM3546), FITC-
conjugated monoclonal antibodies against CD11b (IM0530), CD64 (IM1604) and FITC-
conjugated mouse IgG1 (IM0639) were obtained from Immunotech Beckman Coulter 
(Marseille, France). 
Cell culture and viability 
HL-60 cells (ECACC no. 88112501) were purchased from the European Collection of Animal 
Cell Cultures (HPA, Porton Down, UK). NB4 and U937 were kindly provided by Dr. M. 
Golemovic (Clinical Hospital Zagreb, Croatia). All cells were passaged routinely in RPMI-
1640 supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 50 U/mL penicillin 
and 50 μg/mL streptomycin in a 5% CO2 humidified atmosphere at 37 °C. For the 
experiments, exponentially growing cells were harvested by centrifugation and resuspended in 
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fresh medium containing 10% FBS. Unless stated otherwise, the cells were seeded at an initial 
cell density of 2x10
5
/mL in BD Falcon six-well plates (BD Biosciences, Franklin Lakes, NJ). 
ATO, rapamycin and other compounds were added to the cultures at the times and 
concentration indicated in the Figure legends. For longer incubations, 0.3 mL of fresh medium 
was added to each well at day 2. Viable cells were determined by trypan blue exclusion and 
quantified using a hemocytometer. 
Cell cycle analysis  
At the end of incubation, cells were collected, washed with ice-cold phosphate buffered saline 
(PBS) and stained directly with PI solution (50 μg/mL of PI, 10 mM Tris, pH 8.0, 10 mM 
NaCl, 10 μg/mL RNase A, 0.1% Igepal) for 30 min. Monoparametric DNA analyses were 
performed on at least 10 000 cells for each sample using the FACSCalibur system and 
CellQuest software (Becton Dickinson). The percentages of cells in different phases of the 
cell cycle and in the sub-G1 region were determined using ModFit software (Becton 
Dickinson).  
MTT assay 
To determine the effects of ATO and rapamycin on the proliferation and viability of HL-60 
and U937 cells, colorimetric assays were performed. Cells were seeded at an initial density of 
1.2x10
4
/well in 96 well culture plates (BD Falcon) and incubated with six different 
concentrations of ATO, rapamycin, and their combinations. After 96 h, 20 µL of MTT 
solution (5 mg thiazolyl blue tetrazolium bromide per 1mL of PBS) were added to each well, 
and cells were incubated for 3 h at 37 °C. After incubation, plates were centrifuged at 250xg 
for 5 min, supernatant was discharged, and remaining crystals were dissolved in 180 µL of 
DMSO. The absorbance of the sample was read at 540 nm (Dynatech MR5000, Dynatech 
Technology, Inc., Horsham, PA, USA). 
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Synergism analysis 
Synergistic effects for the combination of arsenic trioxide and rapamycin were assessed by 
applying the method of Chou and Talalay [21]. Briefly, results of the MTT assay were 
expressed as fractions of cells affected (Fa) in comparison to control and the Combination 
Index (CI) was calculated using CompuSyn software (ComboSyn Inc.). CI>1 indicates 
antagonism, CI=1 indicates additive effects and CI<1 indicates synergism. 
Detection of apoptosis 
After incubation, cells were collected, washed with ice-cold PBS and labeled with annexin V 
– FITC and PI, according to the manufacturer's instructions. Samples were analyzed using the 
FACSCalibur system and Cell Quest software (Becton Dickinson). 
Expression of differentiation markers 
After incubation, cells were collected, washed and incubated with FITC-conjugated 
monoclonal antibodies against CD11b, CD64, or with isotypic (FITC-IgG1) control for 20 
min. Samples were analyzed using a FACSCalibur system and Cell Quest software (Becton 
Dickinson), as previously described [18-20]. Briefly, live cells were gated based upon forward 
and side scatter patterns and a total of 15 000 events were collected for each marker from the 
gated area. Results were expressed as both mean fluorescence intensity (MFI) of the sample 
and percentage of positive cells, with isotypic control MFI levels and percentage deducted 
from all values. 
Isolation of total cell lysates and Western blot analysis 
Cells were seeded at a concentration of 0.3x10
6
/mL in T25 cm
2
 flasks and incubated for 3 or 
24 h. After incubation, cells were collected by centrifugation, washed in ice-cold PBS, 
resuspended in 1x cell lysis buffer containing freshly added 1 mM PMSF and 1 g/ml 
leupeptin, and incubated on ice. After 10 min, cells were disrupted by seven passages through 
a 23-gauge needle. Lysates were incubated on ice for an additional 10 min, and then 
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centrifuged at 14 000 x g for 10 min at 4 °C. The supernatants were collected and stored at -80 
°C. The protein concentration in each sample was determined by a Bio-Rad protein assay. 
Western blot analysis was performed as previously described [20]. Briefly, equal amounts of 
proteins (50 μg) in each sample were loaded on two parallel 8% SDS-polyacrylamide gels. 
Electrophoresis and transfer were carried out using Bio-Rad mini-Protean and mini Trans-Blot 
systems. After transfer, nitrocellulose membranes were blocked in TBS-Tween buffer (25 mM 
Tris, 150 mM NaCl, 0.1% [v/v] Tween 20) containing 5% (w/v) non-fat dried milk for 30 
min. After blocking, the membranes were washed three times in TBS-Tween and incubated 
overnight at 4 °C with primary antibodies diluted (1:20000 for actin; 1:1000 for other 
antibodies) in TBS-Tween containing 5% BSA. After incubation, membranes were washed 
and incubated in appropriate secondary antibodies for 120 min at room temperature. The 
antibody binding was detected using the ECL kit according to the manufacturer’s suggestion.  
Primary patient samples 
Peripheral blood was obtained from patients with newly diagnosed AML (with exclusion of 
APL) at the time of diagnosis. All patients provided written informed consent in accordance 
with the Declaration of Helsinki and the study was approved by the Institutional Review 
Board of the University of Zagreb School of Medicine. Mononuclear cells were isolated by 
density gradient centrifugation with NycoPrep
TM
 1.077 (Fresenius Kabi Norge AS for Axis-
Shield PoC AS, Oslo, Norway) and further purified by overnight adherence to plastic. The 
next day, cells were collected, washed, resuspended in fresh RPMI-1640 medium 
supplemented with 20% FBS and seeded at an initial density of 1.0x10
6
/well in 96-well plates 
(BD Falcon). Cell viability was tested by MTT assay after 96-hours incubation with ATO (0.5 
or 1 µM), rapamycin (20 nM), ATRA (1 µM) or their combination. Each experiment was 
done in triplicate and results are expressed as percentage of control. 
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Statistical analysis 
Data are shown as means ± SEM. The Student’s t -test was used to assess the difference 
between each group and control, and one-way analysis of variance (ANOVA), followed by 
Tukey’s multiple comparison test, was used to assess the difference between dual-compound 
treated cells versus cells treated with the same concentration of each agent alone. Statistical 
significance was considered to be achieved when p<0.05. 
 
 
Results 
 
 Sensitivities of a typical APL, and two AML cell lines lacking t(15;17) translocation, 
were tested first by measuring the sub-G1 fraction of propidium labeled cells 24–48 h after the 
addition of increasing doses of ATO. As shown in Figure 1a, the addition of ATO 
significantly increased the sub-G1 fraction of NB4 cells carrying typical t(15;17) 
translocation. The HL-60 cell line was derived from a patient that was initially considered to 
have APL or AML-M3, but had atypical clinical and cytogenetic features and was more 
appropriately classified as an acute myeloblastic leukemia with maturation (AML-M2) [22]. 
As previously reported [5, 6], the sensitivity of myeloblastic HL-60 and promonocytic U937 
cell lines to ATO was low, and the sub-G1 fraction of HL-60 cells was significantly increased 
only after addition of the highest concentration of ATO (5 M). Therefore, we next tested 
whether the addition of rapamycin might potentiate the effects of ATO in non-APL AMLs.  
 Colorimetric MTT assays were performed on HL-60 and U937 cells that were 
incubated in the presence of ATO (0.25–16 M), rapamycin (5-320 nM), and the combination 
of agents for 96 h. As shown in Figure 1b, the presence of rapamycin alone, when applied at 
doses that are therapeutically achievable, had no marked effects on the proliferation of 
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leukemia cells. However, adding increasing doses of rapamycin to ATO resulted in increased 
cytotoxicity when lower concentrations of ATO were used. In U937 cells, combination 
indices that were calculated using CompuSyn software were below 0.3 for the combination of 
low doses of rapamycin (10-20 nM) and low doses of ATO (0.5-1 M), indicating that the 
interaction between rapamycin and ATO was highly synergistic. The inhibitory effects of 
these concentrations of rapamycin and ATO on the number of viable cells were further 
confirmed using a hemocytometer and trypan blue staining (Figure 1c). 
 To further characterize the mechanism of synergistic effects in AML cell lines, the 
effects of 20 nM rapamycin on the percentage of sub-G1 in control and ATO-treated HL-60 
and U937 cells were tested. As shown in Figure 2a, no significant increase in the sub-G1 
fraction was measured 48 h after addition of drugs. Annexin V/PI staining confirmed that no 
significant increase in the percentage of annexin V positive cells could be observed 48 h after 
exposure (Figure 2b). However, longer (96 h) incubation of cells with the combination of 20 
nM rapamycin and 1 M ATO significantly increased the percentage of apoptotic cells. 
Previous studies demonstrated that some growth-arresting properties of rapamycin are due to 
arrest in G0/G1 phase [19, 20]. To test the effects of the combination of agents, cell cycle 
analyses were performed on HL-60 and U937 cells that were incubated in the presence of the 
drugs for 24 h. As shown in Figure 2c, rapamycin significantly reduced the percentage of HL-
60 cells in S phase and U937 cells in G2/M phase, while the percentage of cells arrested in 
G0/G1 phase was significantly higher following treatment with the combination of agents. 
 Rapamycin-mediated effects may be limited by activation of feedback mechanisms 
resulting in survival signals, including engagement of both ERK and Akt signaling pathways 
[16, 23, 24]. To study the effects of the combination of the agents on the activity of ERK, 
Western blot analyses were performed on total cell lysates isolated from HL-60 and U937 
cells treated with ATO (0.5 and 1 M), 20 nM rapamycin, and the combination of agents for 
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30 min. As shown in Figure 3a, the basal level of Thr389 phosphorylated p70 S6K, a 
downstream target of an activated mTOR, was high in U937 cells, as previously described 
[20], but the presence of 20 nM rapamycin completely abolished the phosphorylation in 
control and ATO-treated HL-60 and U937 cells. In U937 cells, rapamycin alone induced an 
increase in the level of Thr202/Tyr204 phosphorylated MAPK that was inhibited by the 
addition of ATO (Figure 3b). In contrast, no increase in the level of phosphorylated MAPK 
was detected in rapamycin-treated HL-60 cells, as previously described [19]. The presence of 
ATO (1 M) alone had modest stimulatory effects on the phosphorylation of both S6K and 
MAPK in HL-60 cells, but no similar effects in U937 cells. To further test for the effects of 
ATO alone on the activity of both signaling pathways in U937 cells, cells were incubated with 
increasing doses of ATO for 3 and 24 h. As shown in Figure 4, longer incubation of U937 
cells with higher doses of ATO inhibits the phosphorylation of both p70 S6K and MAPK.  
 In NB4 cells, ATO-induced inhibition of ERK signaling is correlated with reduced 
levels of an anti-apoptotic protein Mcl-1 [10]. The expression of Mcl-1 has previously been 
reported to decrease as a downstream effect of mTOR inhibition [25]. We studied next the 
levels of Mcl-1 in U937 cells treated with ATO, rapamycin and their combination for 24 h. As 
shown in Figure 5a, the level of Mcl-1 was lower in cells treated with combination of 
rapamycin and higher doses of ATO (1 M). To further test for the activity of other enzymes 
known to mediate proliferative signals, the level of activated Akt was measured in U937 cells. 
In some cancer cell lines, treatment with mTOR complex 1 inhibitors has been reported to 
induce phosphorylation of Akt on Ser473 by negative feedback involving mTOR complex 2 
molecules [16]. As shown in Figure 5b, short duration (3 h) treatment with rapamycin had 
some modest stimulatory effects on the level of phosphorylated Akt, but the level was low 
after 24 h and further decreased in cells treated with the combination of rapamycin and ATO. 
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 When applied in low doses, ATO promotes differentiation of NB4, a typical APL cell 
line [26]. To test for the possible differentiative effects of the combination of ATO and 
rapamycin in U937 cells, the expression of cell surface markers was determined by flow 
cytometry, and the presence of ATRA (1 M) alone or in combination with 20 nM rapamycin 
was used as a positive control [27]. A slight increase in the mean fluorescence intensity (MFI) 
of U937 cells stained with either CD64 (Figure 6a) or CD11b (Figure 6b) was observed after 
96 h incubation in the presence of 1M ATO with no significant increase in the percentage of 
positive cells. Rapamycin alone had no significant effects on the expression of CD11b (Figure 
6b) but significantly decreased both MFI and the percentage of cells expressing a monocytic 
CD64 marker (Figure 6a). When two different concentrations of ATO were added to 
rapamycin pretreated cells, some increase in the expression of CD64 was observed suggesting 
the potential of ATO to overcome a rapamycin-induced decrease in the expression of markers 
of differentiated monocytes. Although the expression of CD11b was significantly higher in 
cells treated with a combination of agents in comparison to control or cells treated with 
rapamycin alone, no significant differences were observed in the level of CD11b expression 
in comparison to cells treated with ATO alone. The possible role of ERK activation in 
rapamycin and ATO-mediated effects on the expression of differentiation markers was further 
tested by the addition of PD 98059, a pharmacological inhibitor of MAPK that acts by 
preventing the activation of an upstream kinase, mitogen-activated protein kinase kinase 
(MAPKK or MEK). As shown in Figure 5c, the pretreatment of cells with PD 98059, at a 
dose (20 M) that was previously shown to inhibit ERK in U937 cells [28], reduced the basal 
level of CD11b and abolished an increase in the expression induced by ATO alone or in 
combination with rapamycin. In addition, PD 98059 significantly reduced the level of CD64 
in control cells as well as the cells treated with rapamycin alone or in the combination with 
ATO.  
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 Finally, combination effects of ATO and rapamycin were examined in primary AML 
cells isolated from the peripheral blood of three AML patients (Table 1). As shown in Figure 
7, AML cells show different sensitivities to increasing doses of ATO, but the lowest number 
of viable cells was detected in cells treated with rapamycin alone or in the combination with 1 
M ATO. 
 
Discussion 
 
 ATO has been shown to exert cytotoxic effects in various solid tumors and non-APL 
leukemias but at concentrations that may not be clinically achievable because of toxicities. 
Therefore, a possible approach to promote generation of its effects at lower concentrations is 
to combine this agent with other drugs that may inhibit growth, promote apoptosis or induce 
differentiation of leukemia cells. The results of the present study show that a combination of 
ATO and rapamycin at therapeutically achievable doses exerts synergistic antiproliferative 
effects in two AML cell lines lacking typical t(15;17) translocation. Similar to results 
obtained by Altman et al. [17], our data confirmed that rapamycin and ATO inhibit the growth 
of cells isolated from peripheral blood of newly diagnosed AML patients. 
 The beneficial effects of the combination of ATO and rapamycin, as measured by 
MTT assay, were more pronounced in promonocytic U937 cells that have been previously 
shown to have a high basal level of phosphorylated p70 S6K [20], a principal downstream 
target of an activated mTOR. Pharmacological inhibitors of mTOR are known to exert 
multiple effects on cell metabolism [29], and the effects of drugs that target metabolism are 
known to depend on the intrinsic metabolic characteristics of the used leukemia cell line [30]. 
It is important to note that tetrazolium dye reduction is dependent on NAD(P)H-dependent 
oxidoreductase enzymes and that formazan deposits increase in metabolically active and 
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decrease in quiescent viable cells. Therefore, results of MTT assays may be misleading as 
they depend more on the metabolic activity of the cell than on the viability itself [31]. 
However, results obtained by trypan blue exclusion confirmed that the addition of rapamycin 
significantly potentiated the inhibitory effects of ATO on the number of viable HL-60 and 
U937 cells.  
 The results of this study indicate that the synergistic effects of the combination of 
drugs at low concentrations may be partially explained by potentiation of apoptosis. In U937 
cells, ATO (1 M) alone increases the percentage of annexin V-positive cells and decreases 
the phosphorylation of ERK, while rapamycin alone decreases the percentage of annexin V-
positive cells and increases the ERK activity. As rapamycin-mediated activation of ERK is 
reduced by co-treatment with ATO, these results suggest that co-treatment with ATO 
efficaciously reduces survival via ERK inhibition. Regarding the effects on the 
PI3K/Akt/mTOR signaling pathway, both ATO and rapamycin reduce the phosphorylation of 
p70 S6K, a downstream target of activated mTOR. In various cancer cell lines, treatment with 
mTORC1 inhibitors such as rapamycin induces upregulation of Akt phosphorylation by a 
negative feedback effect [16]. However, previous studies have suggested that some cell lines 
(including U937 cells) and primary AML cells showed dose-dependent alterations in p-Akt 
levels after prolonged treatment with an mTOR inhibitor [32, 33]. Results of our study that 
revealed a modest increase in the level of Ser473-phosphorylated Akt in rapamycin-treated 
U937 cells after short-term treatment (3 h) and a decrease after longer treatment (24 h) are 
consistent with previous reports in U937 cells [32, 34]. Again, the lowest levels of Ser473 
phosphorylated Akt protein were detected in cells treated with combination of rapamycin and 
ATO suggesting that a part of  the antiproliferative effects of ATO and rapamycin may be due 
to inhibition of Akt signaling pathway. 
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Similar to results reported previously, the presence of low doses of ATO alone for 24 
h had no effects on cell cycle distribution of both HL-60 and U937 cells [35]. In contrast, the 
addition of rapamycin affected cell cycle transition and significantly increased the percentage 
of ATO-treated U937 cells arrested in G1 phase. The mechanism responsible for rapamycin-
mediated growth arrest in G1 phase is well described in many cell types, including leukemia 
cells [20, 27], but recent studies indicated that activated mTOR may have a role in other 
phases, including G2/M cell transition [36]. As the G2/M phase has been described to be the 
most sensitive to arsenite-induced apoptosis in U937 cells [6], the significant decrease in the 
percentage of U937 cells in G2/M phase observed in our study may be partially due to the 
synergistic effects of rapamycin-induced arrest in cell cycle and ATO-mediated toxicity.  
 In addition to protective and antiapoptotic effects, the activation of ERK is commonly 
attributed to have a role in differentiation of myeloid leukemia cell lines [37], including PMA-
mediated differentiation of U937 cells into macrophages [38] or SET-induced differentiation 
into dendritic-like cells [39]. Both ATO and rapamycin have been previously described to 
induce some differentiation; ATO induced the expression of differentiation markers at doses 
that are too low to induce apoptosis [26, 40] and rapamycin only at concentrations that are 
much higher than the range of therapeutically achievable doses [41]. However, at the 
concentration used in our study, rapamycin enhanced expression of CD11b in response to 
ATRA [19, 28] and vitamin D3 [42], and had no effects in cells treated with PMA [19] or 
DMSO [20]. The results of the present study show some modest increase in the level of 
CD11b in ATO-treated cells but these levels were not significantly enhanced by the addition 
of rapamycin. However, when the effects of both agents were tested by measuring the levels 
of monocytic marker CD64, ATO and rapamycin exerted different effects and rapamycin 
alone significantly reduced the level of CD64. Although the effects of rapamycin or its 
derivatives on the expression of CD64 in U937 cells have not been reported, a decrease in 
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CD64 surface marker expression has been recently reported in rapamycin-treated human 
macrophages in vitro [43] and similar inhibitory effects on endocytosis were reported in bone 
marrow-derived dendritic cells [44]. In both studies, the inhibitory effects of rapamycin on the 
expression of receptors involved in phagocytosis and antigen uptake occurred independently 
of either M1 and M2 polarization of macrophages [43] or dendritic cell maturation [44] 
suggesting that these effects are not linked to differentiation. In our study, the results obtained 
with MEK-inhibitors suggest that ERK activity may be important for the expression of 
CD11b as a differentiation marker, but the presence of MEK-inhibitor did not prevent 
rapamycin - mediated decrease in CD64. In addition, our recent study showed that the 
presence of 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) increased the activity 
of ERK, decreased the level of phosphorylated p70 S6K and induced the expression of both 
CD11b and CD64 in U937 cells [28]. Since both AICAR and rapamycin have similar effects 
on the activity of signaling pathways, yet different effects on CD64 expression, these results 
further suggest that neither ERK nor p70 S6K activity are responsible for the rapamycin-
mediated CD64 decrease. To conclude, results of this study indicate that the synergistic 
antiproliferative effects of ATO and rapamycin cannot be ascribed to synergistic effects on 
differentiation. 
 In summary, results of the present study show that ATO and rapamycin at 
concentrations that are therapeutically achievable have synergistic antiproliferative effects in 
two AML cell lines lacking typical t(15;17) translocation. As both drugs are already in 
clinical use, these results further support the role that combination therapies may have in non-
APL AML patients. 
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Figure Legends: 
 
Fig. 1 Arsenic trioxide (ATO) decreases AML cell viability in a dose-dependent manner 
and acts in synergy with rapamycin 
a) NB4, HL-60 and U937 cells were seeded at an initial concentration of 2x10
5
/mL and 
incubated for 24 or 48 h with increasing doses of ATO (1-5 µM) or vehicle (control). After 
incubation, cells were stained with propidium iodide and the proportion of sub-G1 fraction 
was determined using flow cytometry. b) HL-60 and U937 cells were treated with increasing 
concentrations of ATO (0.25-16 µM), rapamycin (5-320 nM) and their combination (0.25 
µM+5 nM - 16 µM+320 nM). After 96 h, cell viability was determined using MTT assay. The 
Combination Index (CI) was calculated using CompuSyn software. CI < 1 indicates 
synergism, CI = 1 indicates additive effects and CI > 1 indicates antagonism. Fa = fraction of 
cells affected. x = lowest concentration of the agent used. c) Cells were preincubated with 
rapamycin (20 nM) or vehicle (control) for 20 minutes before addition of ATO (0.5 and 1 
µM). After 96 h, the number of viable cells was determined by trypan blue exclusion. Results 
are means ± SEM of at least three independent experiments. * p<0.05 (Student t-test) with 
respect to control. § p<0.05 (ANOVA and Tukey test) with respect to either agent alone. 
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Fig. 2 Effects of arsenic trioxide (ATO) and rapamycin on apoptosis and cell cycle 
progression 
HL-60 and U937 cells were incubated with vehicle (control), ATO (0.5 and 1 µM), rapamycin 
(20 nM) or their combination. Rapamycin was added 20 minutes prior to addition of ATO. a) 
The percentage of sub-G1 fraction after 48 h incubation. b) The percentage of annexin V-
FITC positive (upper bars, annexin+/PI-; lower bars, annexin+/PI+) cells after 48 and 96 h. *p 
< 0.05 (Student t-test) with respect to control for annexin+/PI- cells. #p < 0.05 (Student t-test) 
with respect to control for annexin+/PI+ cells. c) The percentage of cells in G0/G1, S and 
G2/M phases of cell cycle after 24 h. * p<0.05 (Student t-test) with respect to control. Results 
are means ± SEM of at least three independent experiments. 
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Fig. 3 Effects of arsenic trioxide (ATO), rapamycin and their combination on the 
activity of mTOR and MAPK in HL-60 and U937 cell lines 
Rapamycin (20 nM) or vehicle (control) were added to HL-60 and U937 cells 20 min before 
ATO (0.5 or 1 µM), and incubated for 30 min. After incubation, total cell lysates were 
isolated, loaded on two parallel gels and analyzed for the expression of phosphorylated and 
total proteins. a) The level of Thr389 phosphorylated and total p70 S6K. b) The level of 
Thr202/Tyr204 phosphorylated and total MAPK. All blots were reprobed with anti-β-actin 
antibodies to verify equal loadings. 
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Fig. 4 Effects of increasing doses of arsenic trioxide (ATO) on the activity of mTOR and 
MAPK in U937 cells after 3 and 24 h 
U937 cells were incubated with increasing doses of ATO (0.5 – 2 M) for 3 and 24 h. After 
incubation, total cell lysates were isolated, loaded on two parallel gels and analyzed for the 
expression of phosphorylated and total proteins. a) The level of Thr389 phosphorylated and 
total p70 S6K. b) The level of Thr202/Tyr204 phosphorylated and total MAPK. All blots 
were reprobed with anti-β-actin antibodies to verify equal loadings. 
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Fig. 5 Effects of arsenic trioxide (ATO), rapamycin and their combination on the levels 
of Mcl-1 and Ser473 phosphorylated Akt in U937 cells 
Rapamycin (20 nM) or vehicle (control) were added to U937 cells 20 min before ATO (0.5 or 
1 µM), and incubated for 3 or 24 h. After incubation, total cell lysates were isolated, loaded 
on two parallel gels and analyzed for the expression of phosphorylated and total proteins. a) 
The level of Mcl-1. b) The level of Ser473 phosphorylated and total Akt. All blots were 
reprobed with anti-β-actin antibodies to verify equal loadings. 
 
 
 
Fig. 6 Effects of rapamycin and arsenic trioxide (ATO) on the expression of 
differentiation markers in U937 cells 
U937 cells were incubated for 96 h with vehicle (control), rapamycin (20 nM), MEK inhibitor 
PD 98059 (20 µM), ATO (0.5 or 1 µM), ATRA (1 µM) or their combination. Results are 
presented as mean fluorescence intensity (MFI) or percentage of CD64- and CD11b-positive 
cells. a) Effects of ATO, ATRA and rapamycin on the expression of CD64. b) Effects of 
ATO, ATRA and rapamycin on the expression of CD11b. c) Effects of PD 98059 on 
rapamycin- and ATO-mediated effects. Results are means ± SEM of at least three 
independent experiments. * p<0.05 (Student t-test) with respect to control. § p<0.05 (ANOVA 
and Tukey test) with respect to either agent alone. 
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Fig. 7 Effects of rapamycin, arsenic trioxide (ATO) and their combination on cells 
isolated from peripheral blood of newly diagnosed AML patients.  
AML cells were incubated for 96 hours with vehicle (control), ATO (0.5 or 1 µM), rapamycin 
(20 nM), ATRA (1 µM) or their combination and cell viability was determined using MTT 
assay. Results are means of experiments done in triplicate and are presented as percentage of 
control. 
 
 
